Sangamo Therapeutics, Inc. (SGMO) earnings
SGMO earnings moved a median of +3.00% by the close. Quarterly and annual SGMO reports and results, each read against the price at its own news timestamp. Back to the SGMO overview →
31 measured SGMO earnings events.
Where these SGMO earnings landedvs 31 measured SGMO earnings reactions
| Middle 50% of SGMO earnings reactions | -4.02% to +6.91% |
|---|---|
| Median reaction (to close) | +3.00% |
| Measured reactions | 31 |
Point-in-time · zero look-ahead
Half of the 31 SGMO earnings events with a measured close landed between -4.02% and +6.91%; 58% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q SANGAMO THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +3.85% | |
| Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Press release | +0.00% | +3.85% | |
| Sangamo Therapeutics Announces First Quarter 2026 Earnings Call | Press release | +2.92% | +10.62% | |
| Form 10-K/A SANGAMO THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -1.17% | -6.88% | |
| Form 10-K SANGAMO THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -1.44% | +7.35% | |
| Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call | Press release | -0.20% | -5.09% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | +11.93% | +9.64% | |
| Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results | Press release | +11.93% | +9.64% | |
| Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call | Press release | +0.93% | +3.00% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | -5.31% | +1.53% | |
| Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results | Press release | -5.31% | +1.53% | |
| Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call | Press release | -3.34% | +4.10% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | -6.33% | -2.95% | |
| Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day | Press release | -6.33% | -2.95% | |
| Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results | Press release | -6.33% | -2.95% | |
| Sangamo Therapeutics Announces First Quarter 2025 Earnings Call | Press release | -2.51% | +3.44% | |
| Form 10-K SANGAMO THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -1.00% | -6.92% | |
| Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference | Press release | -6.60% | -1.89% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | +13.34% | +8.44% | |
| Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results | Press release | +13.34% | +8.44% | |
| Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast | Press release | -1.66% | +19.34% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | -4.04% | -13.44% | |
| Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results | Press release | -4.04% | -13.44% | |
| Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast | Press release | +7.00% | +11.80% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | -0.66% | +5.92% | |
| Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results | Press release | -0.66% | +5.92% | |
| Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast | Press release | +1.29% | +6.47% | |
| Form 10-K SANGAMO THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -1.74% | -10.78% | |
| Form 10-Q SANGAMO THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -2.66% | -15.52% | |
| Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results | Press release | -2.66% | -15.52% | |
| Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast | Press release | +3.88% | -0.10% |
Keep exploring
More SGMO: analyst actions → · SEC filings → · SGMO overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EIDOS THERAPEUTICS (EIDX) | 300 | +0.01% | 51% |
| Grifols, S.A. - American Depositary Shares (GRFS) | 300 | -0.13% | 39% |
| Merit Medical Systems, Inc. (MMSI) | 299 | -0.03% | 48% |
| PLx Pharma Inc. (PLXP) | 299 | -0.05% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.